ME Therapeutics

What ME Therapeutics does

ME Therapeutics Holdings, Inc. is a preclinical-stage biotechnology company founded in 2014 in Vancouver, Canada, focused on discovering and developing next-generation immuno-oncology therapeutics that reprogram immune cells in vivo to recognize and fight cancer. The company's core technological premise is that myeloid-cell-driven immune suppression is a central barrier in many solid tumors and certain hematologic malignancies, and that targeting myeloid biology can unlock durable anti-tumor responses where existing T-cell-directed therapies fail.

The pipeline spans five distinct modalities anchored on the company's in vivo reprogramming platform. The lead asset is a humanized anti-G-CSF monoclonal antibody (h1B11-12) designed to neutralize immune suppression in the tumor microenvironment; it has shown safety in non-human primate toxicology studies and is protected by granted patents in the US and China. Second, myeloid-targeted prodrug candidates (D094, D099) selectively interfere with suppressive myeloid pathways. Third, therapeutic mRNAs (STING activators) delivered via NanoVation Therapeutics' long-circulating lipid nanoparticle (lcLNP) platform have demonstrated synergy with PD-1 checkpoint inhibitors in preclinical colorectal cancer models. Fourth, an in vivo CAR-T and CAR-M program delivers genetic instructions directly into patients to reprogram immune cells in situ, potentially avoiding the ~$500,000-per-patient cost of ex vivo CAR-T manufacturing. Fifth, an exclusively licensed nanobody-based CD22 binder from the National Research Council of Canada extends the in vivo CAR approach into relapsed/refractory B-cell cancers.

ME Therapeutics is publicly listed on the Canadian Securities Exchange (METX) since October 2023 and on the Frankfurt Stock Exchange (Q9T) since December 2023, and is pursuing an uplisting to Nasdaq or NYSE American. The company has no commercial products and generates no product revenue; funding to date consists of small non-brokered private placements totaling approximately CAD $2 million and non-dilutive NRC IRAP grants totaling approximately CAD $190,000. The business model is entirely pre-commercial: value is expected to be realized through future pharmaceutical partnerships, licensing transactions, or acquisition, with first-in-human clinical trials targeted for late 2026 or early 2027. The company employs 11-50 people, is led by founder-CEO Dr. Salim Dhanji, and supplements its scientific team with senior commercial leadership including CBO Karim Lalji.

Name

ME Therapeutics

Legal name

ME Therapeutics Holdings, Inc.

Website

https://metherapeutics.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

ME Therapeutics is a preclinical Vancouver-based biotechnology company developing in vivo immune-cell reprogramming therapeutics, including an anti-G-CSF antibody, mRNA-LNP therapies, and in vivo CAR-T and CAR-M programs, targeting myeloid-driven immune suppression in solid and hematologic cancers.

Ownership category

akta.pro rank

Product category

Immuno-oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Bispecific & Multispecific Antibodies (HLAAAAAF), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Immuno-oncology therapeutics
• Myeloid cell therapy
• Cancer immunotherapy drugs
• MRNA lipid nanoparticles
• Monoclonal antibody development

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Private Placement Financing: The company raises capital through non-brokered private placement offerings of units (common shares + warrants) to institutional and retail investors. This is the primary funding mechanism for preclinical development.
2. Government Grants and Support: Funding and advisory services from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support mRNA therapeutic program and preclinical testing. This is non-dilutive funding.
3. Future Licensing and Partnership Revenue: Potential licensing deals and partnerships for drug candidates. The company is exploring strategic transactions and has engaged banks toward potential U.S. listing on Nasdaq or NYSE American.
4. Equity Listing and Trading: Publicly listed on Canadian Securities Exchange (CSE: METX) and Frankfurt Stock Exchange (FSE: Q9T). Market-based valuation provides liquidity for investors and potential access to broader capital markets.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels10 records

Core offering

ME Therapeutics is a preclinical-stage biotechnology company discovering and developing next-generation immuno-oncology therapeutics that reprogram immune cells in vivo to recognize and fight cancer. Its pipeline includes a humanized anti-G-CSF antibody (h1B11-12), myeloid-targeted small molecule prodrugs (D094, D099), STING-activating therapeutic mRNAs delivered via lipid nanoparticles, and in vivo CAR cell therapy programs (CAR-T and CAR-M) using a licensed CD22 nanobody binder. The company does not yet sell commercial products and is advancing toward first-in-human clinical trials targeted for late 2026 or early 2027.

Product overview

ME Therapeutics is developing a multi-modality immuno-oncology pipeline focused on reprogramming immune cells to fight cancer. The company's portfolio includes: (1) G-CSF Antibody Candidate (h1B11-12), a humanized monoclonal antibody targeting immune suppression in tumors; (2) Myeloid Targeted Prodrug Candidates (D094 and D099), small molecule drugs targeting suppressive myeloid cells; (3) Therapeutic mRNA Candidates encoding immune-modulating proteins delivered via LNP technology from NanoVation Therapeutics; (4) In Vivo CAR Cell Therapy Program using genetic engineering to reprogram immune cells directly in the body; and (5) CD22 Nanobody-based CAR Binder licensed from NRC for next-generation CAR-T and CAR-M therapies. The company leverages lipid nanoparticle (LNP) delivery technology as a core enabling platform across multiple programs.

Differentiator

Problem solved

Functional benefit

Products and services

• G-CSF Antibody Candidate (h1B11-12) A humanized, high-affinity monoclonal antibody that binds to and blocks granulocyte colony-stimulating factor (G-CSF) to overcome immune suppression in the tumor microenvironment. The company's most advanced preclinical asset, intended for cancer treatment indications including solid tumors.
• Myeloid Targeted Prodrug Candidates (D094 and D099) Small molecule prodrug candidates designed to specifically target suppressive myeloid cells in the tumor environment, with the active component interfering with key pathways involved in immune suppression and cancer growth.
• Therapeutic mRNA Candidates (STING activators) mRNA-based drug candidates encoding immune-modulating proteins that activate the STING pathway to stimulate anti-cancer immune responses, delivered via lipid nanoparticle technology from NanoVation Therapeutics. Demonstrated synergy with PD-1 checkpoint inhibitors in preclinical colorectal cancer models.
• In Vivo CAR Cell Therapy Program Next-generation immunotherapy program that delivers genetic instructions directly into a patient's body to reprogram immune cells (T cells and macrophages) within the tumor microenvironment using CAR technology, including in vivo CAR-T and CAR-M approaches, eliminating the need for ex vivo cell manufacturing.
• CD22 Nanobody-based CAR Binder Nanobody-based CD22 binder exclusively licensed from the National Research Council of Canada for use in CAR therapy applications including in vivo CAR-T and CAR-M approaches, providing an alternative target for relapsed/refractory B-cell cancers where CD22 expression is often maintained after CD19 CAR-T failure.

Quantifiable outcome

• STING activator demonstrated synergy with PD-1 checkpoint inhibitors in preclinical colorectal cancer models
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered supporting and core.

• Luckosky Brookman LLPsupportingImplementation/ SI/ Consulting Partner · 30 January 2026Corporate and securities law firm engaged to assist ME Therapeutics in evaluating and pursuing a potential listing on Nasdaq or NYSE American, working alongside investment banks toward this goal.
• National Research Council of Canada (NRC)coreTechnology or Integration · 15 October 2025Technology license agreement dated October 15, 2025 granting ME Therapeutics exclusive commercial rights to NRC's proprietary nanobody-based CD22 binder for use in CAR therapy applications including in vivo CAR-T and CAR-M approaches. The license covers multiple territories (Australia, Brazil, Canada, China, Europe, India, Israel, Japan, New Zealand, Singapore, South Korea, and the United States). The CD22 nanobody is currently being evaluated in an investigator-driven Phase 1 clinical trial (NCT06208735).
• Lucosky Brookman LLPsupportingImplementation/ SI/ Consulting Partner · 3 March 2025Distinguished corporate finance and securities law firm retained to assist in evaluating an uplisting to senior national securities exchanges such as Nasdaq Capital Market or NYSE. The firm brings extensive experience in corporate finance, mergers and acquisitions, and securities law.
• University of British Columbia (Dr. Kenneth Harder Lab)coreStrategic or Co-development Partner · 18 July 2024Ongoing collaboration with Dr. Kenneth Harder's laboratory at UBC for joint research on G-CSF in cancer and novel LNP formulation discovery. Dr. Harder is an Associate Professor in Dept. of Microbiology and Immunology and member of Networks of Centres of Excellence (NCE) Nanomedicine Innovation Network (NMIN).
• NanoVation Therapeutics Inc.coreStrategic or Co-development Partner · 8 July 2024Strategic collaboration announced July 2024 to test delivery and efficacy of mRNA-based drug candidates targeted to myeloid cells using NanoVation's cutting-edge lipid nanoparticle (LNP) technologies. The partnership leverages NanoVation's long-circulating LNP (lcLNP) technology for efficient nucleic acid delivery to immune cells. Initial stage involves testing delivery of two undisclosed target mRNAs to tumor-associated myeloid cells in vivo in mouse colon cancer models. The companies share expertise in myeloid-focused immuno-oncology and RNA delivery.
• Dr. Kate Hanham (Clinical Consultant)supportingOthers · 29 May 2024Clinical trial consultant with strategic input experience ranging from startup biotechnology to top ten pharmaceutical companies. Brings expertise in clinical, regulatory and manufacturing strategies from early development through NDA, with experience in FDA and international regulatory agency communications.
• Dr. Katherine Morris (Clinical Consultant)supportingOthers · 29 May 2024Surgical oncologist and solid tumor immunologist with over 20 years of experience, specializing in gastrointestinal cancers. Completed training at Memorial Sloan Kettering Cancer Center with research focus on G-CSF role in cancer. Member of NIH Cellular Immunotherapy of Cancer study section.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MeTherapeutics
• Facebookfacebook.com/profile.php?id=61564337262455
• LinkedInlinkedin.com/company/me-therapeutics
• Instagraminstagram.com/metherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ME Therapeutics